Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2006-10-17 11:32:11 UTC |
---|
Update Date | 2022-03-07 02:49:25 UTC |
---|
HMDB ID | HMDB0005039 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Sildenafil |
---|
Description | Sildenafil is a drug used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH), developed by the pharmaceutical company Pfizer. It was initially studied for use in hypertension (high blood pressure) and angina pectoris (a form of ischaemic cardiovascular disease). Phase I clinical trials under the direction of Ian Osterloh suggested that the drug had little effect on angina, but that it could induce marked penile erections; Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum. The molecular structure of sildenafil is similar to that of cGMP and acts as a competitive binding agent of PDE5 in the corpus cavernosum, resulting in more cGMP and better erections. Without sexual stimulation, and therefore lack of activation of the NO/cGMP system, sildenafil should not cause an erection. Other drugs that operate by the same mechanism include tadalafil (Cialis) and vardenafil (Levitra); Sildenafil citrate, sold under the names Viagra, Revatio and generically under various other names, is a drug used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH), developed by the pharmaceutical company Pfizer. Viagra pills are blue and diamond-shaped with the words 'Pfizer' on one side, and 'VGR xx' (where xx stands for '25', '50' or '100', the dose of that pill in milligrams) on the other. Its primary competitors on the market are tadalafil (Cialis), and vardenafil (Levitra). |
---|
Structure | CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1 InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29) |
---|
Synonyms | Value | Source |
---|
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine | ChEBI | Aphrodil | Kegg | 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulphonyl)-4-methylpiperazine | Generator | Caverta | HMDB | Revatio | HMDB | Sildenafil citrate | HMDB | Viagra | HMDB | Desmethyl sildenafil | HMDB | Hydroxyhomosildenafil | HMDB | 1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate | HMDB | Lactate, sildenafil | HMDB | NCX-911 | HMDB | Nitrate, sildenafil | HMDB | Acetildenafil | HMDB | Sildenafil nitrate | HMDB | NCX 911 | HMDB | Homosildenafil | HMDB | Citrate, sildenafil | HMDB | Sildenafil, desmethyl | HMDB | Desmethylsildenafil | HMDB | Sildenafil lactate | HMDB |
| Show more...
---|
Chemical Formula | C22H30N6O4S |
---|
Average Molecular Weight | 474.576 |
---|
Monoisotopic Molecular Weight | 474.204924168 |
---|
IUPAC Name | 5-{2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1-methyl-3-propyl-1H,4H,7H-pyrazolo[4,3-d]pyrimidin-7-one |
---|
Traditional Name | revatio |
---|
CAS Registry Number | 139755-83-2 |
---|
SMILES | CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1 |
---|
InChI Identifier | InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29) |
---|
InChI Key | BNRNXUUZRGQAQC-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Benzenesulfonamides |
---|
Direct Parent | Benzenesulfonamides |
---|
Alternative Parents | |
---|
Substituents | - Benzenesulfonamide
- Pyrazolopyrimidine
- Benzenesulfonyl group
- Phenoxy compound
- Phenol ether
- Alkyl aryl ether
- Pyrimidone
- N-methylpiperazine
- N-alkylpiperazine
- Piperazine
- Pyrimidine
- Organosulfonic acid amide
- 1,4-diazinane
- Pyrazole
- Sulfonyl
- Organosulfonic acid or derivatives
- Organic sulfonic acid or derivatives
- Azole
- Heteroaromatic compound
- Tertiary aliphatic amine
- Tertiary amine
- Lactam
- Ether
- Azacycle
- Organoheterocyclic compound
- Organooxygen compound
- Organonitrogen compound
- Hydrocarbon derivative
- Organic nitrogen compound
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Organosulfur compound
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Sildenafil,1TMS,isomer #1 | CCCC1=NN(C)C2=C1N([Si](C)(C)C)C(C1=CC(S(=O)(=O)N3CCN(C)CC3)=CC=C1OCC)=NC2=O | 3859.8 | Semi standard non polar | 33892256 | Sildenafil,1TMS,isomer #1 | CCCC1=NN(C)C2=C1N([Si](C)(C)C)C(C1=CC(S(=O)(=O)N3CCN(C)CC3)=CC=C1OCC)=NC2=O | 3901.2 | Standard non polar | 33892256 | Sildenafil,1TMS,isomer #1 | CCCC1=NN(C)C2=C1N([Si](C)(C)C)C(C1=CC(S(=O)(=O)N3CCN(C)CC3)=CC=C1OCC)=NC2=O | 5427.6 | Standard polar | 33892256 | Sildenafil,1TBDMS,isomer #1 | CCCC1=NN(C)C2=C1N([Si](C)(C)C(C)(C)C)C(C1=CC(S(=O)(=O)N3CCN(C)CC3)=CC=C1OCC)=NC2=O | 3980.5 | Semi standard non polar | 33892256 | Sildenafil,1TBDMS,isomer #1 | CCCC1=NN(C)C2=C1N([Si](C)(C)C(C)(C)C)C(C1=CC(S(=O)(=O)N3CCN(C)CC3)=CC=C1OCC)=NC2=O | 4171.5 | Standard non polar | 33892256 | Sildenafil,1TBDMS,isomer #1 | CCCC1=NN(C)C2=C1N([Si](C)(C)C(C)(C)C)C(C1=CC(S(=O)(=O)N3CCN(C)CC3)=CC=C1OCC)=NC2=O | 5372.7 | Standard polar | 33892256 |
| Show more...
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Sildenafil GC-MS (Non-derivatized) - 70eV, Positive | splash10-006t-9004300000-55c87eff7b6ad40ea3d5 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Sildenafil GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Sildenafil LC-ESI-qTof , Positive-QTOF | splash10-0059-2494500000-e3f8387aee5a0463363c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sildenafil LC-ESI-qTof , Positive-QTOF | splash10-05s0-3892000000-aa19715309275e16a6c0 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sildenafil , positive-QTOF | splash10-0059-2494500000-e3f8387aee5a0463363c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Sildenafil , positive-QTOF | splash10-05s0-3892000000-aa19715309275e16a6c0 | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sildenafil 10V, Positive-QTOF | splash10-004i-0002900000-b281f59f40caaba85ac9 | 2015-04-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sildenafil 20V, Positive-QTOF | splash10-004i-4436900000-0c5804e76b9d495c76d6 | 2015-04-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sildenafil 40V, Positive-QTOF | splash10-0459-6292000000-5a32bfcdda2067978be9 | 2015-04-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sildenafil 10V, Negative-QTOF | splash10-00di-0001900000-51b4957d0b3d25c41773 | 2015-04-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sildenafil 20V, Negative-QTOF | splash10-01vk-0302900000-86c63c2fd17f7c5b7d6f | 2015-04-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sildenafil 40V, Negative-QTOF | splash10-03dj-8916100000-e941afc576d544ed32a7 | 2015-04-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sildenafil 10V, Positive-QTOF | splash10-004i-0000900000-c92b21b6524ea5040313 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sildenafil 20V, Positive-QTOF | splash10-004i-0000900000-06d94f4626e8bee6e389 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sildenafil 40V, Positive-QTOF | splash10-006t-9101300000-ef50cfadb7bd34e88187 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sildenafil 10V, Negative-QTOF | splash10-00di-0000900000-1617a2dfdf2b96a0cd2c | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sildenafil 20V, Negative-QTOF | splash10-0002-0010900000-744efa093f1de0f36d62 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sildenafil 40V, Negative-QTOF | splash10-003r-0272900000-aa5d9fef9c0fb52ad923 | 2021-09-24 | Wishart Lab | View Spectrum |
| Show more...
---|
Biological Properties |
---|
Cellular Locations | Not Available |
---|
Biospecimen Locations | Not Available |
---|
Tissue Locations | |
---|
Pathways | |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB00203 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB023606 |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 5023 |
---|
KEGG Compound ID | C07259 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Sildenafil |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 5212 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 9139 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Dunn, Peter James; Wood, Albert Shaw. Process for preparation of Sildenafil by cyclization. Eur. Pat. Appl. (1997), 18 pp. |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Kekilli M, Beyazit Y, Purnak T, Dogan S, Atalar E: Acute myocardial infarction after sildenafil citrate ingestion. Ann Pharmacother. 2005 Jul-Aug;39(7-8):1362-4. Epub 2005 May 24. [PubMed:15914518 ]
- Kim NN, Goldstein I, Moreland RB, Traish AM: Alpha-adrenergic receptor blockade by phentolamine increases the efficacy of vasodilators in penile corpus cavernosum. Int J Impot Res. 2000 Mar;12 Suppl 1:S26-36. [PubMed:10845762 ]
- Warrington JS, Shader RI, von Moltke LL, Greenblatt DJ: In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos. 2000 Apr;28(4):392-7. [PubMed:10725306 ]
- Chua R, Keogh A, Miyashita M: Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant. 2005 Apr;24(4):498-500. [PubMed:15797756 ]
- Fekete F, Fabian E: [Effectiveness and adverse effects of sildenafil in erectile dysfunction]. Orv Hetil. 2000 Jan 16;141(3):115-8. [PubMed:10693332 ]
- Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, Corbin JD: Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol. 2004 Jul;66(1):144-52. [PubMed:15213306 ]
|
---|